These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 22444104)

  • 1. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.
    Shah E; Pimentel M
    Aliment Pharmacol Ther; 2014 May; 39(9):973-83. PubMed ID: 24612075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?
    Purslow C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):263. PubMed ID: 22816171
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Sultan S; Chang L; Heidelbaugh JJ; Smalley W; Verne GN
    Gastroenterology; 2022 Jul; 163(1):137-151. PubMed ID: 35738725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
    Chang L; Sultan S; Lembo A; Verne GN; Smalley W; Heidelbaugh JJ
    Gastroenterology; 2022 Jul; 163(1):118-136. PubMed ID: 35738724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
    Black CJ; Burr NE; Quigley EMM; Moayyedi P; Houghton LA; Ford AC
    Gastroenterology; 2018 Dec; 155(6):1753-1763. PubMed ID: 30144426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
    Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lubiprostone: in constipation-predominant irritable bowel syndrome.
    Carter NJ; Scott LJ
    Drugs; 2009 Jun; 69(9):1229-37. PubMed ID: 19537839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.
    Lacy BE
    Aliment Pharmacol Ther; 2018 Oct; 48(8):817-830. PubMed ID: 30194692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugs for Irritable Bowel Syndrome.
    Med Lett Drugs Ther; 2020 Mar; 62(1594):25-32. PubMed ID: 32324172
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.